Tempus AI is expanding its partnership with Verastem Oncology to develop a companion diagnostic (CDx) for the latter’s ...

The partnership builds on the success of Verastem’s Phase 2 RAMP-201 clinical trial, which led to the U.S. Food and Drug Administration’s accelerated approval of a combination therapy for KRAS ...

Tempus completed confirmatory testing in Verastem’s Phase 2 RAMP-201 clinical trial, which evaluated the combination of avutometinib and defactinib to treat recurrent low-grade serous ovarian ...

Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, today announced new data to be presented at the 2025 American Society of ...

Cizzle Bio, Inc. announced today the online publication of a new study abstract in conjunction with the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, projecting that its ...

Moreover, previous studies have suggested that more conservative options can be successfully used for low-risk, early-stage ...

Pachter, and Sanjib Chowdhury at Verastem (Needham, MA). Three additional applications from Verastem and Boundless Bio (San Diego) followed in 2023–2025. ORIC-114 is being developed by Oric ...

Other drugs in the class – Gilead Sciences' Zydelig (idelalisib), Bayer's Aliqopa (copanlisib) and Verastem's Copiktra (duvelisib) – have been approved for blood cancers like leukaemia and ...

Healthcare & Pharmaceuticalscategory· May 8, 2025 US FDA approves Verastem's ovarian cancer therapy The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients ...